|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:adjuvants
|
may be included
|
|
gptkbp:administered_by
|
injection
|
|
gptkbp:available_at
|
nasal sprays
microneedles
oral routes
|
|
gptkbp:benefits
|
long-lasting immunity
strong immune response
safety profile
|
|
gptkbp:can_be_combined_with
|
other vaccines
|
|
gptkbp:can_be_used_in
|
gptkb:animals
gptkb:humans
|
|
gptkbp:challenges
|
production costs
public perception
regulatory hurdles
|
|
gptkbp:clinical_trial
|
required for efficacy
|
|
gptkbp:collaboration
|
government agencies
academic institutions
international organizations
|
|
gptkbp:community_health
|
gptkb:significant
|
|
gptkbp:development
|
genetic engineering
|
|
gptkbp:example
|
gptkb:HPV_vaccine
gptkb:Hepatitis_B_vaccine
gptkb:Zoster_vaccine
|
|
gptkbp:global_access
|
is a concern
|
|
gptkbp:historical_significance
|
first developed in the 1980s
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
recombinant vaccine
|
|
gptkbp:invention
|
may affect availability
|
|
gptkbp:is_compared_to
|
inactivated vaccines
live attenuated vaccines
|
|
gptkbp:is_designed_for
|
gptkb:cancer_treatment
allergy treatment
|
|
gptkbp:manufacturer
|
biotechnology companies
|
|
gptkbp:notable_work
|
gptkb:Ebola_vaccine
COVID-19 vaccines
Rabies vaccine
|
|
gptkbp:participated_in
|
B-cell response
T-cell response
|
|
gptkbp:prevention
|
infectious diseases
|
|
gptkbp:produces
|
antigens
|
|
gptkbp:regulatory_compliance
|
required before use
|
|
gptkbp:requires
|
boosters
|
|
gptkbp:research_ongoing_for
|
new applications
|
|
gptkbp:safety_measures
|
is essential post-approval
|
|
gptkbp:storage
|
cold chain
|
|
gptkbp:targets
|
specific pathogens
|
|
gptkbp:trends
|
therapeutic vaccines
m RNA technology
personalized vaccines
|
|
gptkbp:uses
|
recombinant DNA technology
|
|
gptkbp:bfsParent
|
gptkb:hepatitis_B_vaccine
gptkb:Engerix-B
gptkb:H1_N1_influenza_virus
gptkb:Feline_Leukemia
|
|
gptkbp:bfsLayer
|
5
|